Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Maher

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
Oncotargets and Therapy|July 10, 2023
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current PerspectivesJohn Maher
Current Gene Therapy|December 25, 2013
Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cellsJohn Maher
ISRN Oncology|January 11, 2013
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsJohn Maher
Foot (Edinburgh, Scotland)|March 5, 2017
Patient reported outcomes six months following surgical treatment of end stage hallux rigidus in a community based podiatric surgery serviceAnthony John Maher
Therapeutic Advances in Vaccines and Immunotherapy|June 12, 2020
CAR T-cell immunotherapy of B-cell malignancy: the story so farLeena Halim, John Maher
Molecular Cancer Therapeutics|September 6, 2018
Strategies to Address Chimeric Antigen Receptor Tonic SignalingAdam Ajina, John Maher
Biology|December 30, 2025
Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune DiseaseMadeleine Osborne, John Maher
Expert Review of Clinical Immunology|January 28, 2026
CAR-T cell immunotherapy of malignant melanomaOlha Kharasakhal, John Maher
Experimental Biology and Medicine (Maywood, N.J.)|February 23, 2026
How can we balance risk and benefit of interleukin-18 armored T cell therapies?Paulina Vicenova, John Maher
Archivum Immunologiae Et Therapiae Experimentalis|December 13, 2021
Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted ImmunotherapiesRoberta Mazza, John Maher
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
Oncotargets and Therapy|July 10, 2023
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current PerspectivesJohn Maher
Current Gene Therapy|December 25, 2013
Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cellsJohn Maher
ISRN Oncology|January 11, 2013
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsJohn Maher
Foot (Edinburgh, Scotland)|March 5, 2017
Patient reported outcomes six months following surgical treatment of end stage hallux rigidus in a community based podiatric surgery serviceAnthony John Maher
Therapeutic Advances in Vaccines and Immunotherapy|June 12, 2020
CAR T-cell immunotherapy of B-cell malignancy: the story so farLeena Halim, John Maher
Molecular Cancer Therapeutics|September 6, 2018
Strategies to Address Chimeric Antigen Receptor Tonic SignalingAdam Ajina, John Maher
Biology|December 30, 2025
Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune DiseaseMadeleine Osborne, John Maher
Expert Review of Clinical Immunology|January 28, 2026
CAR-T cell immunotherapy of malignant melanomaOlha Kharasakhal, John Maher
Experimental Biology and Medicine (Maywood, N.J.)|February 23, 2026
How can we balance risk and benefit of interleukin-18 armored T cell therapies?Paulina Vicenova, John Maher
Archivum Immunologiae Et Therapiae Experimentalis|December 13, 2021
Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted ImmunotherapiesRoberta Mazza, John Maher
Pageof 14